Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of majo…
Biotechnology
US, New York [HQ]
AXSM/Financial Reporting
Income Statements
11 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | - - | - - | - - | - - | 50.00 | 270.00 | |
|
EPS
|
-0.17 | -0.47 | -0.88 | -1.42 | -1.27 | -1.15 | -2.05 | -2.83 | -3.59 | -4.86 | -5.27 | |
| Diluted in mil. | -0.17 | -0.47 | -0.88 | -1.42 | -1.27 | -1.15 | -2.05 | -2.83 | -3.59 | -4.86 | -5.27 | |
|
Profit
|
- - | - - | - - | - - | - - | - - | - - | - - | -1.00 | 44.00 | 237.00 | |
| Gross Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | 89.61 | 87.84 | |
| Pre Tax | -2.00 | -6.00 | -10.00 | -27.00 | -28.00 | -30.00 | -68.00 | -102.00 | -130.00 | -187.00 | -238.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | -373.99 | -88.06 | |
| ETR | - - | 40.29 | -12.88 | -2.16 | -4.48 | -9.72 | -1.96 | -2.42 | -3.48 | -5.68 | -0.40 | |
| Net | -2.00 | -6.00 | -10.00 | -27.00 | -28.00 | -30.00 | -69.00 | -105.00 | -134.00 | -197.00 | -239.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | -395.24 | -88.41 | |
| EBITDA | -1.00 | -2.00 | -6.00 | -27.00 | -26.00 | -32.00 | -67.00 | -99.00 | -124.00 | -170.00 | -176.00 | |
| EBITDA Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | -341.62 | -65.07 | |
| Operating Income | -1.00 | -5.00 | -9.00 | -27.00 | -27.00 | -32.00 | -67.00 | -99.00 | -124.00 | -176.00 | -182.00 | |
| Operating Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | -352.74 | -67.59 | |
| Interest Income | - - | 2.00 | - - | - - | - - | - - | 1.00 | 2.00 | 5.00 | 7.00 | - - | |
| Loss | -1.00 | -5.00 | -9.00 | -27.00 | -26.00 | -32.00 | -67.00 | -99.00 | -124.00 | -226.00 | -453.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -5.00 | -32.00 | |
|
Operating Expenses
|
-1.00 | -5.00 | -9.00 | -27.00 | -26.00 | -32.00 | -67.00 | -99.00 | -124.00 | -221.00 | -420.00 | |
| R&D | -1.00 | -4.00 | -6.00 | -21.00 | -19.00 | -23.00 | -53.00 | -70.00 | -58.00 | -57.00 | -97.00 | |
| G&A | - - | -1.00 | -2.00 | -6.00 | -7.00 | -9.00 | -13.00 | -28.00 | -66.00 | -123.00 | -222.00 | |
| SG&A | - - | -1.00 | -2.00 | -6.00 | -7.00 | -9.00 | -13.00 | -28.00 | -66.00 | -159.00 | -323.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | -35.00 | -100.00 | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -5.00 | -6.00 | |
| Interest Expenses | - - | -2.00 | - - | - - | -1.00 | -1.00 | -1.00 | -2.00 | -5.00 | -7.00 | -6.00 | |
| Other Expenses | - - | -2.00 | -2.00 | - - | - - | -2.00 | -1.00 | -3.00 | -5.00 | -10.00 | -55.00 | |
|
WA Shares Outstanding
|
12.00 | 12.00 | 11.00 | 19.00 | 22.00 | 26.00 | 34.00 | 37.00 | 37.00 | 40.00 | 45.00 | |
| Diluted | 12.00 | 12.00 | 11.00 | 19.00 | 22.00 | 26.00 | 34.00 | 37.00 | 37.00 | 40.00 | 45.00 |